<DOC>
	<DOCNO>NCT02008084</DOCNO>
	<brief_summary>The purpose pilot study learn study factor important design large , full-scale study effect TRIA-662 serum triglyceride ( TG ) high-density lipoprotein cholesterol ( HDL-C ) level . In study , patient first enter Single-blind , dietary-controlled baseline period receive 1000 mg placebo active drug three time daily meal ( i.e. , breakfast , lunch , dinner ) 6 - 8 week . If qualify continue , receive 2000 mg active placebo drug additional 14 week . Active drug give 48 patient placebo drug give 16 patient . However , neither patient clinic staff know patient active placebo drug end study .</brief_summary>
	<brief_title>A Pilot Study Evaluate Lipid Effects TRIA-662</brief_title>
	<detailed_description>The primary objective pilot study ass feasibility large , full-scale study would evaluate regulating effect TRIA-662 serum triglyceride ( TG ) high-density lipoprotein cholesterol ( HDL-C ) level . In study , patient first enter Single-blind , dietary-controlled baseline period receive 1000 mg placebo active drug three time daily meal ( i.e. , breakfast , lunch , dinner ) 6 - 8 week . Upon completion 6 8 -week dietary-controlled baseline period , subject meet inclusion exclusion criterion randomize double-blind treatment period . In double-blind treatment period patient randomize least 48 subject randomize TRIA-662 least 16 patient randomize placebo ( 3:1 ratio ) . The forced-dose titration achieve follow : Weeks 1 - 2 : Two 500 mg tablet three time daily meal ( total daily dose 3000 mg ) ; Weeks 3 - 14 : Two 1000 mg tablet three time daily meal ( total daily dose 6000 mg ) . Investigational product administer three time daily meal ( i.e. , breakfast , lunch , dinner ) . Down titration 3000 mg daily ( two 500 mg tablet , three time daily ) allow event patient tolerate 6000 mg daily treatment stipulate period . Under scenario , down-titrated patient remain tolerate dose remainder study . Lipid ancillary exploratory parameter evaluate baseline period , upon randomization throughout active treatment period . Throughout study , patient must adhere heart-healthy diet , abstain from/minimize ethyl alcohol intake control variable may alter serum lipid level ( e.g. , exercise , weight loss program , drug include counter agent preparation may alter serum lipid level . Safety tolerability assess throughout trial evaluation physical exam , electrocardiogram ( ECGs ) , routine hematology blood chemistry testing , vital sign adverse event .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Hyperlipidemia , Familial Combined</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type V</mesh_term>
	<mesh_term>Lipidoses</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<criteria>1 . Women childbearing potential must negative serum pregnancy test screen Visit 4 Women consider childbearing potential : 1. hysterectomy tubal ligation prior Visit 1 . 2. postmenopausal ( 12 month menses menopausal follicle stimulate hormone level ) Women childbearing potential must agree use effective method birth control throughout study . Acceptable mean birth control include : implantable contraceptive , injectable contraceptive , oral contraceptive , transdermal contraceptive , intrauterine device , male female condom spermicide , abstinence , sterile sexual partner . 2 . Patients Weeks 4 2 demonstrate mean LDLC level lipidmodifying drug therapy indicate accord investigator judgment ATP III guideline . 3 . Patients demonstrate mean serum triglyceride = &gt; 200 mg/dL ( 2.26 mmol/L ) &lt; = 500 mg/dL ( 5.65 mmol/L ) measure 2 sequential visit dietary control baseline period ( Visits 2 3 Visits 3 3a ) low level within 25 % upper level ( high value minus low value ) /higher value &lt; 0.25 ) . 4 . Patients willing maintain stable diet physical activity level throughout study 5 . Patients willing able sign information consent form follow protocol include availability visits/telephone followup approximately 24 week . 1. pregnant , plan become pregnancy study , nurse 2. clinically significant electrocardiographic abnormality Visit 1 4 3. body mass index &gt; 45 kg/m2 Visit 1 4. weight change &gt; 5 % initial body weight Visit 1 4 5. poorly control diabetes define hemoglobin A1c &gt; 9.5 % prior Visit 4 6. evidence hepatic disease ( ALT AST great 2.0 upper limit normal ( ULN ) , bilirubin &gt; 1.5 ULN , cirrhosis ) visit 1 7. renal dysfunction define glomerular filtration rate ( GFR ) &lt; 60 mL/min/1.73 m2 Visit 1 8. hypothyroidism treat stable least 6 month prior study entry 9. poorly control hypertension define mean systolic blood pressure &gt; 160 mm Hg and/or diastolic blood pressure &gt; 100 mmHg Visit 1 . In individual endorgan damage , mean systolic blood pressure &gt; 140 mmHg mean diastolic blood pressure &gt; 90 mmHg Visit 1 10. severe hypotension define systolic blood pressure = &lt; 90 mm Hg diastolic blood pressure = &lt; 60 mm Hg AND symptomatic 11. active peptic ulcer 12. know intolerance allergy niacin ( nicotinic acid ) , niacinamide ( nicotinamide ) , tablet ingredient : 1methylnicotinamide chloride , microcrystalline cellulose , povidone , silicified microcrystalline cellulose , crospovidone , anhydrous dibasic calcium phosphate , hydroxypropyl cellulose , magnesium stearate ( vegetable origin ) , polyvinyl alcohol , titanium dioxide , talc , polyethylene glycol , methacrylic acid copolymer , sodium bicarbonate . 13. known history coronary artery disease , cerebrovascular disease peripheral arterial disease 14 . Use screen conclusion study follow lipid modify medications/supplements : 1 . Niacin ( nicotinic acid ) niacinamide ( nicotinamide ) 2 . Fibrates/fibric acid derivative like fenofibrate , gemfibrozil , clofibrate 3 . Bile acid sequestrants like cholestyramine , colesevelam , colestipol 4 . HMGCoA reductase inhibitor ( statin ) include atorvastatin , cerivastatin , fluvastatin , lovastatin , pravastatin , simvastatin , rosuvastatin 5 . Ezetimibe 6 . Omega3 fatty acid 7 . Supplements contain flaxseed , tryptophan , fish oil , algal oil . 8 . Sterol/stanol product 9 . Red yeast rice supplement soy isoflavone supplement . 10 . Dietary fiber supplement include &gt; 2 teaspoonfuls MetamucilÂ® psyllium contain supplement per day . 11 . Other natural health product prescription agent judge investigator potential alter serum lipid level individual subject . 15. history angina myocardial infarction 16. hyperuricemia history gouty arthritis 17. know nephritic syndrome &gt; 3 g protein/day urine Visit 1 18. know familial lipoprotein lipase deficiency , apo CII deficiency , familial dysbetalipoproteinemia . 19. requirement peritoneal dialysis hemodialysis renal insufficiency . 20. history malignancy , except patient diseasefree &gt; 5 yr , resect basal squamous cell skin carcinoma cervical carcinoma situ . 21. history bariatric surgery . 22. history pancreatitis , except secondary cholelithiasis . 23. anticipation major surgery study . 24. treatment weight loss drug program trial . 25. treatment HIVprotease inhibitor , cyclophosphamide isotretinoin . 26. treatment tamoxifen , estrogens , progestins stable &gt; 4 week prior screen Visit 1 27. routine anticipate use systemic corticosteroid Visit 1 . Local , topical , inhaled , nasal corticosteroid permit 28. blood donation &gt; pint ( 0.5 L ) within 30 day prior screen , plasma donation within 7 day prior screen Visit 1 29. consumption &gt; 14 alcoholic drink per week ( 1 drink = 12 oz beer , 5 oz wine , 1.5 oz hard liquor ) Visit 1 . 30. history drug abuse Visit 1 31. participation another clinical trial within 30 day sign information consent form . 32. noncompliant single blind investigational product ( &lt; 80 % investigational product ) diet per local judgment Visit 1 4 . 33 . Any condition therapy investigator believe might pose risk make participation study patient 's best interest . 34 . Poor mental function reason expect difficulty complying requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>hypertriglyceridemia</keyword>
	<keyword>mixed hyperlipidemia</keyword>
</DOC>